Why Is Oxford Biomedica Up Today?
Oxford Biomedica shares rose 2.58% today to 517p, a gain of 13p, according to the market data provided, valuing the cell and gene therapy manufacturer at about £610 million.
There was no new announcement today. The gain extends a recovery that began after interim results on 22 September, when management reiterated all its guidance following a sharp share price fall in August.
Key Highlights
In the six months to 30 June 2026, Revenue rose 9% to £79.8 million, or 10% at constant currency. Adjusted operating EBITDA improved to a loss of £2.5 million from a loss of £3.9 million a year earlier.
OXB signed 17 new clients in the first half, more than 30% above the total signed in the whole of 2025, and its client programme portfolio expanded by 34%.
Management reiterated FY 2026 revenue guidance of £180 million to £200 million at constant currency and expects FY 2027 revenue growth of 25-30%.
About Oxford Biomedica
OXB is a global contract development and Manufacturing organisation (CDMO) specialising in cell and gene therapies. It produces viral vectors, such as lentiviral and AAV vectors, which are essential for delivering genetic material in advanced therapies. It operates sites in the UK, France and the US.
For LSE:OXB, the key indicators are revenue growth, new client wins, contracted order coverage, gross margins and EBITDA.
Key Reasons Behind Today's Uptick
In August, OXB cut its 2026 revenue guidance from £220-240 million to £180-200 million, blaming a short-term shift in client ordering behaviour, deferrals and delayed programmes. The shares fell around 20% on the news.
Since then, investors have been reassured that the problem is timing rather than weak demand. Around £168 million of the 2026 revenue guidance was already covered by contracted orders at the interim stage, giving good visibility. The shares rose after the interims despite the revenue miss against analyst forecasts.
Capacity Expansion
OXB's manufacturing Facility in Durham, North Carolina, is now online for GMP production, strengthening its position in the important US market. The company has also launched fast-track offerings for AAV and lentiviral vector platforms and selected the first programmes for its VectorXcellerator initiative, which supports earlier collaboration with clients.
Profitability Path
OXB expects a mid-single-digit EBITDA Margin in 2026, excluding one-off costs, and at least double-digit margins in 2027. Its long-term ambition is revenue of £500 million by 2030, with EBITDA margins approaching 30%.
Gross margin fell to 37% from 43% in the first half, reflecting product and client mix and one-off comparisons, so margin recovery is an important watch point.
Growth Catalysts
Conversion of the growing client pipeline into revenue is the key catalyst. Strong growth in 2027 would put OXB firmly on the path to sustainable profits. Additional commercial approvals for cell and gene therapies made using OXB's vectors could also drive longer-term demand.
The cell and gene therapy market is still at an early stage, and outsourcing to specialist manufacturers is common because producing viral vectors at scale is complex and expensive. That structural trend supports OXB's Long-term Growth ambitions.
Risks
The August guidance cut shows how volatile CDMO revenues can be when clients delay programmes. The company remains loss-making on a reported basis, and competition from larger CDMOs is intense. Funding conditions for biotech clients also affect demand.
Iran War and Its Impact on Oxford Biomedica
The Iran conflict affects OXB mainly through inflation, interest rates and biotech funding. Brent Crude traded around $105 a barrel on 29 September. Higher rates can make it harder for smaller biotech clients to raise money, potentially slowing programmes.
Energy costs at manufacturing sites are another consideration, though healthcare Demand is generally less sensitive to geopolitics than consumer sectors.
Valuation
At 517p, OXB's Market Value of about £610 million compares with 2026 revenue guidance of £180-200 million. That multiple looks reasonable if 2027 growth of 25-30% and double-digit margins are delivered, but leaves room for disappointment if delays continue.
What Investors Should Watch Next
Investors should monitor order conversion, second-half revenue delivery, gross margins, new client wins and 2027 guidance.
Conclusion
Oxford Biomedica's 2.58% rise today reflects growing confidence that August's guidance cut was a temporary setback. Record client wins and new US capacity support the outlook, but execution in the second half is crucial.






Please wait processing your request...